T1	CHEM 17 30	pentoxifilina
#1	AnnotatorNotes T1	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T2	CHEM 848 851	PTX
#2	AnnotatorNotes T2	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T3	DISO 79 94	diabetes tipo 2
#3	AnnotatorNotes T3	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T4	CHEM 2123 2126	PTX
#4	AnnotatorNotes T4	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T5	CHEM 122 134	angiotensina
#5	AnnotatorNotes T5	C0003018; Angiotensins; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T6	PROC 136 177	ensayo clínico doble ciego y aleatorizado
#6	AnnotatorNotes T6	C0013072; Double-Blind Method; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity
T7	PROC 868 886	De forma aleatoria
#7	AnnotatorNotes T7	C0034656; Randomization; Research Activity
T8	CHEM 209 215	renina
#8	AnnotatorNotes T8	C0035094; Renin; Amino Acid, Peptide, or Protein · Enzyme
T9	CHEM 216 228	angiotensina
#9	AnnotatorNotes T9	C0003018; Angiotensins; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T10	PROC 252 263	tratamiento
#10	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	DISO 280 300	nefropatía diabética
#11	AnnotatorNotes T11	C0011881; Diabetic Nephropathy; Disease or Syndrome
T12	DISO 363 379	enfermedad renal
#12	AnnotatorNotes T12	C0022658; Kidney Diseases; Disease or Syndrome
T13	CHEM 423 430	agentes
#13	AnnotatorNotes T13	C0450442; Agent; Chemical Viewed Functionally
T14	PROC 451 477	ensayo clínico doble ciego
#14	AnnotatorNotes T14	C0013072; Double-Blind Method; Research Activity + C0008976; Clinical Trials; Research Activity
T15	CHEM 534 537	PTX
#15	AnnotatorNotes T15	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T16	CHEM 519 532	pentoxifilina
#16	AnnotatorNotes T16	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T17	PROC 1139 1147	tratados
#17	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	DISO 561 572	proteinuria
#18	AnnotatorNotes T18	C0033687; Proteinuria; Finding
T19	DISO 590 605	diabetes tipo 2
#19	AnnotatorNotes T19	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T20	DISO 607 610	DM2
#20	AnnotatorNotes T20	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T21	CHEM 665 668	PTX
#21	AnnotatorNotes T21	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T22	CHEM 639 651	angiotensina
#22	AnnotatorNotes T22	C0003018; Angiotensins; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T23	DISO 939 950	proteinuria
#23	AnnotatorNotes T23	C0033687; Proteinuria; Finding
T24	PROC 975 986	tratamiento
#24	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	CHEM 1002 1011	enalapril
#25	AnnotatorNotes T25	C0014025; enalapril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T26	CHEM 1152 1160	losartán
#26	AnnotatorNotes T26	C0126174; losartan; Organic Chemical · Pharmacologic Substance
T27	CHEM 1163 1172	enalapril
#27	AnnotatorNotes T27	C0014025; enalapril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T28	PROC 1199 1210	tratamiento
#28	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	CHEM 1270 1278	losartán
#29	AnnotatorNotes T29	C0126174; losartan; Organic Chemical · Pharmacologic Substance
T30	CHEM 1280 1289	enalapril
#30	AnnotatorNotes T30	C0014025; enalapril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T31	CHEM 1306 1319	pentoxifilina
#31	AnnotatorNotes T31	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T32	CHEM 1483 1493	creatinina
#32	AnnotatorNotes T32	C0010294; creatinine; Organic Chemical · Biologically Active Substance
T33	ANAT 1494 1500	sérica
#33	AnnotatorNotes T33	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T34	CHEM 1221 1224	PTX
#34	AnnotatorNotes T34	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T35	ANAT 1538 1546	urinaria
#35	AnnotatorNotes T35	C0042036; Urine; Body Substance
T36	CHEM 1550 1559	proteínas
#36	AnnotatorNotes T36	C0033684; Proteins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T37	ANAT 1640 1648	urinaria
#37	AnnotatorNotes T37	C0042036; Urine; Body Substance
T38	CHEM 1652 1660	proteína
#38	AnnotatorNotes T38	C0033684; Proteins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T39	PROC 1989 2005	presión arterial
#39	AnnotatorNotes T39	C0005824; Blood pressure determination; Health Care Activity
T40	CHEM 2062 2072	creatinina
#40	AnnotatorNotes T40	C0010294; creatinine; Organic Chemical · Biologically Active Substance
T41	PROC 2254 2275	filtración glomerular
#41	AnnotatorNotes T41	C0017654; Glomerular Filtration Rate; Diagnostic procedure
T42	DISO 2293 2296	DM2
#42	AnnotatorNotes T42	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T43	CHEM 2157 2160	PTX
#43	AnnotatorNotes T43	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T44	CHEM 2324 2336	angiotensina
#44	AnnotatorNotes T44	C0003018; Angiotensins; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T45	DISO 50 61	proteinuria
#45	AnnotatorNotes T45	C0033687; Proteinuria; Finding
T46	ANAT 111 134	sistema de angiotensina
#46	AnnotatorNotes T46	C0035096; Renin-angiotensin system; Body System
T47	ANAT 201 228	sistema renina-angiotensina
#47	AnnotatorNotes T47	C0035096; Renin-angiotensin system; Body System
T48	DISO 302 304	ND
#48	AnnotatorNotes T48	C0011881; Diabetic Nephropathy; Disease or Syndrome
T49	ANAT 374 379	renal
#49	AnnotatorNotes T49	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T50	ANAT 628 651	sistema de angiotensina
#50	AnnotatorNotes T50	C0035096; Renin-angiotensin system; Body System
T51	CHEM 991 999	losartán
#51	AnnotatorNotes T51	C0126174; losartan; Organic Chemical · Pharmacologic Substance
T52	DISO 934 936	ND
#52	AnnotatorNotes T52	C0011881; Diabetic Nephropathy; Disease or Syndrome
T53	PROC 1483 1500	creatinina sérica
#53	AnnotatorNotes T53	C0201976; Creatinine measurement, serum (procedure); Laboratory Procedure
T54	PROC 1502 1507	HbA1c
#54	AnnotatorNotes T54	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T55	ANAT 1517 1525	arterial
#55	AnnotatorNotes T55	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
T56	PROC 1509 1525	presión arterial
#56	AnnotatorNotes T56	C0005824; Blood pressure determination; Health Care Activity
T57	CHEM 1608 1611	PTX
#57	AnnotatorNotes T57	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T58	CHEM 1904 1907	PTX
#58	AnnotatorNotes T58	C0030899; pentoxifylline; Organic Chemical · Pharmacologic Substance
T59	ANAT 1997 2005	arterial
#59	AnnotatorNotes T59	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
T60	PROC 2040 2072	aclaramiento medio de creatinina
#60	AnnotatorNotes T60	C0373595; Creatinine clearance measurement; Laboratory Procedure
T61	ANAT 2313 2336	sistema de angiotensina
#61	AnnotatorNotes T61	C0035096; Renin-angiotensin system; Body System
T62	LIVB 65 74	pacientes
#62	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	LIVB 337 346	pacientes
#63	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T66	LIVB 576 585	pacientes
#64	AnnotatorNotes T66	C0030705; Patients; Patient or Disabled Group
T67	Dose 722 728	400 mg
T68	Frequency 729 736	diarios
T71	LIVB 920 929	pacientes
#65	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group
T72	Duration 1020 1039	al menos tres meses
T73	LIVB 1081 1097	grupo de control
#66	AnnotatorNotes T73	C0009932; Control Groups; Group
T74	LIVB 1110 1117	hombres
#67	AnnotatorNotes T74	C0025266; Male population group; Population Group
T75	LIVB 1123 1130	mujeres
#68	AnnotatorNotes T75	C0043210; Woman; Population Group
T76	LIVB 1237 1244	hombres
#69	AnnotatorNotes T76	C0025266; Male population group; Population Group
T77	LIVB 1250 1257	mujeres
#70	AnnotatorNotes T77	C0043210; Woman; Population Group
T78	Dose 1292 1298	400 mg
T79	Frequency 1298 1302	/día
T80	Duration 1328 1335	6 meses
T82	LIVB 1460 1469	pacientes
#71	AnnotatorNotes T82	C0030705; Patients; Patient or Disabled Group
T84	PHYS 1528 1546	excreción urinaria
#72	AnnotatorNotes T84	C0042034; Urination; Organism Function | C2371165; Urination functions; Organ or Tissue Function
T85	PHYS 1630 1648	excreción urinaria
#73	AnnotatorNotes T85	C0042034; Urination; Organism Function | C2371165; Urination functions; Organ or Tissue Function
T87	Duration 1721 1728	3 meses
T89	Duration 1760 1767	6 meses
T90	LIVB 1800 1816	grupo de control
#74	AnnotatorNotes T90	C0009932; Control Groups; Group
T97	LIVB 2279 2288	pacientes
#75	AnnotatorNotes T97	C0030705; Patients; Patient or Disabled Group
T64	LIVB 1190 1210	grupo de tratamiento
#76	AnnotatorNotes T64	C5205742; Treatment Group; Population Group
T65	ANAT 2265 2275	glomerular
#77	AnnotatorNotes T65	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
T69	Neg_cue 380 382	no
T70	Quantifier_or_Qualifier 389 396	frenado
A1	Assertion T70 Negated
R1	Negation Arg1:T69 Arg2:T70	
T81	CONC 1379 1390	diferencias
A2	Assertion T81 Negated
#78	AnnotatorNotes T81	C1705241; Delta (difference); Quantitative Concept
T83	Neg_cue 1361 1363	no
R2	Negation Arg1:T83 Arg2:T81	
T86	CONC 1837 1844	cambios
A3	Assertion T86 Negated
#79	AnnotatorNotes T86	C0443172; Changed status; Quantitative Concept
T88	Neg_cue 1817 1819	no
R3	Negation Arg1:T88 Arg2:T86	
T91	Quantifier_or_Qualifier 1918 1926	asociado
A4	Assertion T91 Negated
T92	Neg_cue 1908 1910	no
R4	Negation Arg1:T92 Arg2:T91	
T93	Neg_cue 786 792	ningún
T94	CONC 793 801	artículo
A5	Assertion T94 Negated
#80	AnnotatorNotes T94	C1706852; Article; Intellectual Product
R5	Negation Arg1:T93 Arg2:T94	
T95	Observation 4 10	efecto
#81	AnnotatorNotes T95	C1518681; Outcome of Therapy; Finding (?)
R6	Causes Arg1:T1 Arg2:T95	
R7	Experiences Arg1:T62 Arg2:T45	
R8	Experiences Arg1:T62 Arg2:T3	
R9	Experiences Arg1:T62 Arg2:T95	
R10	Experiences Arg1:T62 Arg2:T1	
R11	Overlap Arg1:T45 Arg2:T3	
T98	Quantifier_or_Qualifier 264 271	inicial
#83	AnnotatorNotes T98	C0205265; Initially; Temporal Concept
R12	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T98	
R13	Experiences Arg1:T63 Arg2:T10	
R14	Experiences Arg1:T63 Arg2:T11	
R15	Experiences Arg1:T63 Arg2:T48	
R16	Experiences Arg1:T63 Arg2:T12	
R17	Location_of Arg1:T49 Arg2:T12	
T99	Observation 494 500	efecto
#84	AnnotatorNotes T99	C1518681; Outcome of Therapy; Finding (?)
T100	Quantifier_or_Qualifier 501 512	acumulativo
#85	AnnotatorNotes T100	C1511559; Cumulative; Qualitative Concept
R19	Has_Quantifier_or_Qualifier Arg1:T99 Arg2:T100	
R20	Causes Arg1:T16 Arg2:T99	
R21	Causes Arg1:T15 Arg2:T99	
R22	Experiences Arg1:T66 Arg2:T18	
R23	Experiences Arg1:T66 Arg2:T19	
R24	Experiences Arg1:T66 Arg2:T20	
R25	Overlap Arg1:T18 Arg2:T19	
R26	Overlap Arg1:T18 Arg2:T20	
R27	Experiences Arg1:T66 Arg2:T16	
R28	Experiences Arg1:T66 Arg2:T15	
R29	Experiences Arg1:T66 Arg2:T99	
R30	Has_Dose_or_Strength Arg1:T21 Arg2:T67	
R31	Has_Frequency Arg1:T21 Arg2:T68	
T102	Observation 818 841	efecto antiproteinúrico
R32	Causes Arg1:T2 Arg2:T102	
R33	Has_Dose_or_Strength Arg1:T2 Arg2:T67	
R34	Has_Frequency Arg1:T2 Arg2:T68	
R35	Causes Arg1:T21 Arg2:T102	
T103	Observation 1973 2005	reducción de la presión arterial
#87	AnnotatorNotes T103	C0520854; Decreased mean arterial pressure; Finding
R36	Location_of Arg1:T59 Arg2:T39	
R37	Location_of Arg1:T59 Arg2:T103	
T104	CONC 2018 2035	final del estudio
#88	AnnotatorNotes T104	C2983670; Study End Date; Temporal Concept
R38	Overlap Arg1:T60 Arg2:T104	
R40	Experiences Arg1:T71 Arg2:T52	
R41	Experiences Arg1:T71 Arg2:T23	
R42	Overlap Arg1:T52 Arg2:T23	
R43	Experiences Arg1:T71 Arg2:T24	
R44	Combined_with Arg1:T51 Arg2:T25	
R45	Used_for Arg1:T51 Arg2:T24	
R46	Has_Duration_or_Interval Arg1:T51 Arg2:T72	
R47	Has_Duration_or_Interval Arg1:T25 Arg2:T72	
T105	CONC 1053 1062	incluidos
#89	AnnotatorNotes T105	C1512693; Inclusion; Qualitative Concept
R48	Before Arg1:T24 Arg2:T105	
R49	Experiences Arg1:T73 Arg2:T17	
R50	Experiences Arg1:T74 Arg2:T17	
R51	Experiences Arg1:T75 Arg2:T17	
R52	Used_for Arg1:T26 Arg2:T17	
R53	Combined_with Arg1:T26 Arg2:T27	
R54	Experiences Arg1:T64 Arg2:T28	
R55	Used_for Arg1:T34 Arg2:T28	
R56	Experiences Arg1:T76 Arg2:T28	
R57	Experiences Arg1:T77 Arg2:T28	
R58	Experiences Arg1:T76 Arg2:T29	
R59	Combined_with Arg1:T29 Arg2:T30	
R60	Experiences Arg1:T77 Arg2:T29	
R61	Experiences Arg1:T64 Arg2:T29	
R66	Has_Duration_or_Interval Arg1:T31 Arg2:T80	
R67	Has_Frequency Arg1:T31 Arg2:T79	
R68	Has_Dose_or_Strength Arg1:T31 Arg2:T78	
R62	Combined_with Arg1:T30 Arg2:T31	
T106	CONC 1340 1360	comienzo del estudio
#90	AnnotatorNotes T106	C4684789; Study Start; Temporal Concept
R63	Overlap Arg1:T81 Arg2:T106	
T107	CONC 1413 1452	características demográficas y clínicas
R64	Experiences Arg1:T82 Arg2:T53	
R65	Location_of Arg1:T33 Arg2:T53	
R69	Location_of Arg1:T55 Arg2:T56	
R70	Experiences Arg1:T82 Arg2:T54	
R71	Experiences Arg1:T82 Arg2:T56	
R72	Experiences Arg1:T82 Arg2:T84	
T108	CONC 1630 1660	excreción urinaria de proteína
#91	AnnotatorNotes T108	C3897352; Total Protein Urine Excretion Rate; Quantitative Concept (?)
T109	CONC 1528 1559	excreción urinaria de proteínas
#92	AnnotatorNotes T109	C3897352; Total Protein Urine Excretion Rate; Quantitative Concept (?)
T110	CONC 1664 1674	disminuido
#93	AnnotatorNotes T110	C0547047; Decrease; Quantitative Concept
R73	After Arg1:T110 Arg2:T87	
R74	After Arg1:T110 Arg2:T89	
R76	Experiences Arg1:T90 Arg2:T85	
R78	After Arg1:T86 Arg2:T89	
R79	After Arg1:T86 Arg2:T87	
T111	Observation 1876 1899	efecto antiproteinúrico
R80	Causes Arg1:T58 Arg2:T111	
R81	Has_Quantifier_or_Qualifier Arg1:T111 Arg2:T91	
T112	Observation 1947 1964	cambio metabólico
#94	AnnotatorNotes T112	C4718639; Metabolic changes; Finding
T113	Observation 2193 2216	efecto antiproteinúrico
R82	Causes Arg1:T43 Arg2:T113	
T114	Quantifier_or_Qualifier 2217 2228	acumulativo
#95	AnnotatorNotes T114	C1511559; Cumulative; Qualitative Concept
R83	Has_Quantifier_or_Qualifier Arg1:T113 Arg2:T114	
R84	Location_of Arg1:T65 Arg2:T41	
R86	Experiences Arg1:T97 Arg2:T41	
R87	Experiences Arg1:T97 Arg2:T42	
R88	Experiences Arg1:T97 Arg2:T113	
R89	Experiences Arg1:T97 Arg2:T43	
T116	Observation 350 356	avance
#97	AnnotatorNotes T116	C1457868; Worse; Finding (?)
R90	Has_Quantifier_or_Qualifier Arg1:T116 Arg2:T70	
R91	Before Arg1:T12 Arg2:T116	
#98	AnnotatorNotes T70	C0205421; Deferred; Temporal Concept (?)
T117	Observation 951 962	persistente
#99	AnnotatorNotes T117	C2983415; Persistent Disease; Finding
R94	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T117	
R95	Overlap Arg1:T117 Arg2:T24	
T118	Quantifier_or_Qualifier 1391 1405	significativas
A6	Assertion T118 Negated
#100	AnnotatorNotes T118	C0750502; Significant; Idea or Concept
R77	Has_Quantifier_or_Qualifier Arg1:T81 Arg2:T118	
R96	Negation Arg1:T83 Arg2:T118	
T119	Quantifier_or_Qualifier 1845 1859	significativos
A7	Assertion T119 Negated
#101	AnnotatorNotes T119	C0750502; Significant; Idea or Concept
R97	Has_Quantifier_or_Qualifier Arg1:T86 Arg2:T119	
R98	Negation Arg1:T88 Arg2:T119	
#82	AnnotatorNotes T91	C0332281; Associated with; Qualitative Concept
A8	Experiencer T62 Patient
A9	Experiencer T63 Patient
A10	Experiencer T66 Patient
A11	Experiencer T71 Patient
A12	Experiencer T73 Patient
A13	Experiencer T74 Patient
A14	Experiencer T75 Patient
A15	Experiencer T64 Patient
A16	Experiencer T76 Patient
A17	Experiencer T77 Patient
A18	Experiencer T82 Patient
A19	Experiencer T90 Patient
A20	Experiencer T97 Patient
R18	Has_Result_or_Value Arg1:T39 Arg2:T103	
